-
CME Information or Content Source:This activity has been planned and implemented in accordance with the Essential Areas and policies of the Medical Society of Virginia through the joint providership with Carilion Clinic’s CME Program and OncoLens. Carilion Clinic’s CME Program is accredited by The Medical Society of Virginia to provide continuing medical education for physicians. Carilion Clinic’s CME Program designates this enduring material activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
-
Event Supporter(s):This activity is supported by an educational grant from Pfizer
-
Start Date:June 15, 2023
-
End Date:June 14, 2024
Course Description
Enduring material (EM) featuring expert discussion of Aplastic Anemia, hosted by Carilion Clinic is now available for up to 3 AMA PRA Category 1 Credits™.
Overall Learning Objectives
Following the educational activities, participants will be able to:
- Improve the care of patients through early identification and diagnosis of Aplastic Anemia.
- Have increased awareness of Aplastic Anemia to refer patients to higher clinical centers of reference
- Understand and implement current standards for the treatment for Aplastic Anemia and its complications.
- Standardize the clinical management of special patient subpopulations and difficult cases of Aplastic Anemia patients.
3-Part Aplastic Anemia On-Demand CME Video
You can watch the compilation of all lectures and receive up to 3 AMA PRA Category 1 CreditsTM. To receive credit, be sure to complete the speaker evaluation (required) and then provide any additional information on knowledge, competence, and performance.
- EM Start Date: 6/15/2023
- EM End Date: 6/14/2024
- Evaluation: https://forms.office.com/r/yrbfZAyUyx
A 3-Part Lecture Series on Aplastic Anemia – view all lectures or just select specific ones.
00:00 Promo
00:11 Lecture 1: Pancytopenia: An Old-Fashioned Approach
49:00 Lecture 2: Immunopathogenesis of Aplastic Anemia
1:49:36 Lecture 3: Evolving Immunotherapies & Allogenic Hematopoietic Stem Cell Transplants (HSCT)
2:43:40 Evaluation Reminder
SPEAKER:
Dr. William Fintel, MD
Medical Director, Carilion Clinic
MODERATOR:
Dr. Apostolos Dallas, MD
Associate Professor, Internal Medicine, Virginia Tech Carilion School of Medicine; CME Director, Carilion Clinic
Lecture 1 Objectives: 1. Recognize three general categories of pancytopenia: A. Normocellular marrow B. Hypercellular marrow C. Hypocellular marrow 2. Recognize the Myriad of treatment options, all dependent on a correct diagnosis, to help steer and treat your patient.
SPEAKER:
Dr. Brant Ward, MD, PhD
Assistant Professor of Medicine, Virgina Commonwealth University
MODERATOR:
Dr. Darian Wang, MD
Residency Associate Program Director, Virginia Tech Carilion School of Medicine
Lexture 2 Objectives: 1. Describe the primary and secondary causes of bone marrow aplasia. 2. Identify inherited causes of bone marrow failure. 3. Apply features of inherited immune disorders to the pathogenesis of bone marrow aplasia.
SPEAKER:
Dr. Elizabeth Krieger, MD
Hematology and Oncology, Virgina Commonwealth University
MODERATOR:
Dr. Darian Wang, MD
Residency Associate Program Director, Virginia Tech Carilion School of Medicine
Lecture 3 Objectives: 1. Analyze the genetic predispositions that can lead to bone marrow aplasia. 2. Evaluate the genetic causes of bone marrow aplasia that necessitate modified treatment approaches. 3. Report and comprehend the dynamic landscape of immunosuppressive therapy for the management of aplastic anemia. 4. Examine the role of transplantation as a potential curative treatment option for aplastic anemia. 5. Discuss current and emerging clinical trials exploring treatment strategies for aplastic anemia.
Target Audience
Internal Medicine providers, Hematologists, Medical Oncologists, Pathologists, Primary Care Physicians, Nurses, Mid-Level Providers, Residents, Fellows, and any other members of the hematology care team.
Identification and Mitigation of Disclosure of Financial Relationships
Faculty:
William A. Fintel, MD – Reported no relevant financial relationship(s)/affiliation(s) with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Brant R. Ward, MD, PhD – reported relevant relationships with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.
- Blueprint Medicines – Clinical trial funding
- Swedish Orphan Biovitrum – Clinical research funding (relationship ended)
- AstraZeneca – Clinical trial funding (relationship ended)
- Takeda – Speaker’s Bureau
All reported relevant financial relationships have been identified and mitigated. (A CME Office representative was present at Dr. Ward’s lecture and verified there was no discernible bias toward any ineligible companies.)
Elizabeth Krieger, MD – Reported no relevant financial relationship(s)/affiliation(s) with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Planning Committee:
Apostolos P. Dallas, MD, MACP – Reported Financial Relationships: Stock in GSK (formerly GlaxoSmithKline), AstraZeneca, Ortho-McNeil & Merck. All reported relevant financial relationship(s)/affiliation(s) have been identified and mitigated.
William A. Fintel, MD, Hien Thach, RN, and Linda M. Wells, CHCP reported no relevant financial relationship(s)/affiliation(s) with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
